GS
AVDL

GTS Securities’s Avadel Pharmaceuticals AVDL Stock Holding History

GTS Securities’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-41,700
Closed -$547K – 1468
2024
Q3 		$547K Buy
41,700
+11,800
+39% +$180K ﹤0.01% 2733
2024
Q2 		$420K Sell
29,900
-9,600
-24% -$156K ﹤0.01% 2841
2024
Q1 		$667K Sell
39,500
-35,000
-47% -$521K ﹤0.01% 2331
2023
Q4 		$1.05M Sell
74,500
-26,300
-26% -$309K ﹤0.01% 2134
2023
Q3 		$1.04M Buy
+100,800
New +$1.35M ﹤0.01% 1983

Other funds holding AVDL

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
GJL
Gendell Jeffrey L $7.34B AUM 183.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
WE
Wealth Effects Boston, Massachusetts $282M AUM 62.81% 1-Year Est. Return

GTS Securities's AVDL Position: Q3 2024 in Review

GTS Securities sold out of Avadel Pharmaceuticals (AVDL) in Q3 2024, closing a stake of 53,315 shares — an estimated $812K sold.

GTS Securities first reported a position in AVDL in Q3 2023 and held it in 4 quarters. The position peaked at $1.11M in Q1 2024. 176 funds tracked by Wall St. Rank hold AVDL as of Q3 2024.

  • GTS Securities reported no remaining Avadel Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • GTS Securities sold 53,315 Avadel Pharmaceuticals shares in Q3 2024, an estimated $812K.
  • GTS Securities first reported a position in Avadel Pharmaceuticals in Q3 2023 and held it in 4 quarters.
  • GTS Securities's Avadel Pharmaceuticals position peaked at $1.11M in Q1 2024.
  • 176 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q3 2024.

Based on GTS Securities's 13F filing for Q3 2024, filed 13 Nov 2024.